ArticleClinical journal of gastroenterology2026
Tocilizumab for steroid-refractory hemophagocytic syndrome after durvalumab and tremelimumab for advanced hepatocellular carcinoma.
Yuki Kanayama et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it